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Neural speciﬁcityIn the post combination antiretroviral therapy (cART) era, the prevalence of mild forms of HIV-associated
neurocognitive disorders (HAND) in individuals with HIV-infection remains high. There is a pressing need to
ﬁnd biomarkers that can aid clinical assessment of HAND, especially in those with mild or no neurocognitive
symptoms. Here we hypothesized that a reduction in neural speciﬁcity, or the speciﬁcity of neuronal tuning,
could serve as a potential biomarker of asymptomatic HAND. To directly test this hypothesis, we applied two ad-
vanced fMRI techniques to examine the difference in neural speciﬁcity betweenmiddle-aged HIV+women and
age-matched negative controls, with a focus on the fusiform face area (FFA), a critical region in face processing.
Face discrimination performance was assessed outside of the scanner. While the behavioral performance of face
discrimination was comparable between the two groups, a reduced neural speciﬁcity in the FFA of HIV-positive
womenwas revealed by a novel fMRI analysis technique, local regional heterogeneity analysis, or Hcorr, as well as
an established technique, fMRI-rapid adaptation. In contrast, conventional fMRI techniques were insensitive to
these early changes. These results suggest that, prior to the onset of detectable behavioral deﬁcits, signiﬁcant
neuronal dysfunctions are already present in HIV+ individuals, and these early neuronal dysfunctions can be de-
tected and assessed via neural speciﬁcity,which, in combiningwith the novelHcorr technique, has a strong poten-
tial to serve as a biomarker of asymptomatic HAND and other neurodegenerative diseases.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
While the introduction of combination antiretroviral therapy (cART)
has signiﬁcantly reduced the incidence of HIV-associated dementia
(HAD)— the most severe form of HIV-associated neurocognitive disor-
ders (HAND) (McArthur et al., 1999; McArthur, 2004), the overall prev-
alence of HAND has remained high (Harezlak et al., 2011; Heaton et al.,
2011, 2010; Schouten et al., 2011; Simioni et al., 2010). It has been sug-
gested that about 30–60% of HIV-positive adults are currently living
with HAND (Grant, 2008), and more than half of these individuals
have the mildest form of HAND referred to as asymptomatic
neurocognitive impairment (ANI) (Heaton et al., 2010). This new spec-
trum poses a signiﬁcant challenge in clinical settings to identify those
rather mild cognitive impairments (Moore et al., 2012; Valcour, 2011).
Currently the diagnosis of HAND is based on neuropsychological testing.
While these tests are well developed, many of them are neither sensi-
tive nor speciﬁc to HAND (Haddow et al., 2013; Hasbun et al., 2012;ience, Georgetown University
eservoir Rd. NW, Washington,
0617.
. This is an open access article underSakamoto et al., 2013; Skinner et al., 2009; Valcour et al., 2011), or are
too time-consuming to be used in routine clinical assessment
(Spudich and Ances, 2012). In addition to the development of new neu-
ropsychological testing that is more speciﬁc and more sensitive to
HAND, biomarkers that correlate with disease progression could be ex-
tremely helpful in assisting clinical diagnosis and evaluating therapeutic
effects as they provide a more objective measurement and avoid the
practice effects associated with repetitive behavioral testing
(Ciborowski, 2009; Fox, 2013; Marcotte et al., 2013). However, despite
signiﬁcant progress in research, the reliable detection of HAND (espe-
cially mild forms of HAND)with biomarkers remains amajor challenge.
For instance, recent studies have suggested biomarkers of HIV-disease
might not closely correlate with cognitive impairments in the post-
cART era (Gelman et al., 2013).
In contrast, recent advances in neuroimaging techniques like mag-
netic resonance imaging (MRI) have offered a noninvasiveway to detect
and assess pathological changes due to varying neurodegenerative dis-
eases, including HAND (Descamps et al., 2008; Holt et al., 2012). For in-
stance, structural MRI has revealed volume reduction in varying brain
regions that can be linked to cognitive impairments (Ances et al.,
2012; Chang et al., 2011; Towgood et al., 2012). However, brain atrophy
usually happens at rather late stages of disease with signiﬁcant andthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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sized to affect neuronal function long before changes in anatomy can be
detected, functional MRI (fMRI), with its ability to directly image brain
function, has the potential to be a critical tool in detecting early signs
of HAND particularly in clinically asymptomatic patients. However,
the effectiveness of recent efforts to use fMRI to studyHIV has been lim-
ited by the absence of a clearmodel of howHIV affects theneuronal pro-
cessing that gives rise to behavioral deﬁcits, and how these changes in
neuronal processing could be detected with fMRI at high sensitivity. In-
deed, recent fMRI studies ofHIV have generated some “conﬂicting”ﬁnd-
ings: both increased and decreased neural activity have been reported
in HIV-positive patients (Ances et al., 2008; Castelo et al., 2006; Chang
et al., 2001;Maki et al., 2009;Melrose et al., 2008). These contradictions
might reﬂect the technical limitations of conventional fMRI techniques:
lower activation levels could reﬂect neuronal loss in HIV-infected pa-
tients or highly speciﬁc neuronal tuning in healthy controls (which
would also lead to a decreased number of neurons responding). In con-
trast, higher activation levels could result either from HIV-induced de-
creases in neural speciﬁcity (which would lead to an increase in
number of neurons responding) or from fully functional neuronal pop-
ulations in healthy controls. While these two scenario have very differ-
ent implications for behavioral performance, they cannot be dissociated
using conventional fMRI techniques that rely on comparing average
fMRI response amplitude and cannot measure neural speciﬁcity (Grill-
Spector et al., 2006).
In contrast, a more advanced fMRI technique, fMRI-Rapid Adapta-
tion (fMRI-RA) (Grill-Spector et al., 2006), has proven to be able tomea-
sure neural speciﬁcitymore directly than conventional fMRI techniques,
with a direct link to behavioral performance. In fMRI-RA, the response
to a pair of stimuli presented in rapid succession is measured for pairs
similar or different in a speciﬁc perceptual aspect (e.g., viewpoint or
shape), and the contrast between the combined response level when
the property is the same or different is interpreted as an index of stim-
ulus representational dissimilarity at the neural level (Jiang et al., 2007;
Kourtzi and Kanwisher, 2001). For instance, using fMRI-RA and
morphed face, we (Jiang et al., 2006) and others (Gilaie-Dotan and
Malach, 2007) have provided evidence suggesting that the neural
tuning of FFA neurons in healthy young adults are highly selective/spe-
ciﬁc, in linewith the high performance in discriminating different faces.
In contrast, individuals with autism spectrum disorders (ASD) often
have difﬁculties in discriminating face shapes (Snow et al., 2011). We
have shown that the impaired face discrimination performance can be
quantitatively linked to a decrease in neural speciﬁcity in the FFA, esti-
mated via both fMRI-RA as well as a novel fMRI analysis technique,
local regional heterogeneity analysis, or Hcorr. These results suggest
that neural speciﬁcitymay serve as a sensitivemeasure of neuronal dys-
function. In contrast to fMRI-RA that estimates neural speciﬁcity via the
proﬁle of fMRI response associatedwith stimuli similarity, local regional
heterogeneity analysis, orHcorr, whichwe recently developed, estimates
neural speciﬁcity via voxel-wise correlations. Brieﬂy,Hcorr calculates the
variance of local voxel-wise correlations in a region of interest (ROI),
resulting in a measure of heterogeneity of neural responses in the ROI,
also termed Hcorr, as an indirect measure of neural speciﬁcity (Jiang
et al., 2013). We have recently validated this technique in several inde-
pendent data sets, and provided evidence that varying cognitive perfor-
mance can be quantitatively linked to Hcorr at corresponding brain
regions (Jiang et al., 2013).
Here we hypothesized that, in HIV-infected adults who have sup-
pressed viral load and are cognitively normal, subtle changes of neuro-
nal functions are already present, even in the absence of behavioral
impairments, and these early neuronal dysfunctions can be detected
and assessed via a decrease in neural speciﬁcity. To directly test this hy-
pothesis, we examined the difference in neural speciﬁcity between
middle-aged HIV-positive women who were on cART with suppressed
viral load and matched HIV-negative controls, using the well-
established fMRI-RA, as well as the novel Hcorr technique. Because thetemporal cortex is one of the most affected regions due to HIV-
infection (Kallianpur et al., 2012; Küper et al., 2011; Sarma et al.,
2014; Wiley et al., 1991) and the neural bases of face processing have
been well studied (Kanwisher and Yovel, 2006), we investigated the
neural speciﬁcity in the fusiform face area (FFA), a critical face process-
ing region in the ventral temporal lobe (Kanwisher and Yovel, 2006).
2. Material and methods
2.1. Women3s interagency HIV study (WIHS)
The WIHS was designed to examine the natural and treated history
of HIV disease among women in response to its rising epidemic in
1994–1995. Its study design is detailed elsewhere (Bacon et al., 2005;
Barkan et al., 1998). The original enrollment recruited 2054 HIV-
infected and 569 HIV-uninfected women from six study sites (Chicago,
Los Angeles, San Francisco,Washington, DC, Brooklyn, and the Bronx) in
the United States.Women visit a study site every 6months; during each
visit, structured interviews are performed to collect data on socio-
demographic characteristics, substance use and sexual behaviors, health
care utilization, antiretroviral therapy, other treatments, and disease
outcomes. In addition, physical and obstetric/gynecologic examinations
are performed by themedical staff and biological specimens are collect-
ed. The local Institutional Review Board at each site approved the study
protocol, and all women gave their written informed consent. As of Jan-
uary 2013, about 90% of HIV+ participants in the WIHS were receiving
cART, and among those on cART, about 70% achieved a viral load level of
less than 80 copies/ml.
2.2. Participants
Twenty-eight middle-aged (43–56 years old, mean 50.3 ± 0.8)
women with no major psychiatric disorders or other confounding
health problems participated in this cross-sectional study. There were
15 HIV-positive receiving cART and 13 HIV-negatives. All of them
were recruited from theWashington,DC site of theWomen3s Interagen-
cy HIV Study (WIHS) from visit 36–38 (from year 2012 to year 2013).
The two groups were matched on age, education, and socioeconomic
status and other factors that might affect their brain functions (see
Table 1). HIV+ women with neurologic complications were excluded
from the study. Data from one additional HIV+ woman was excluded
as she was 60 years old (while the oldest HIV− control was 56 years
old), though including her data yielded nearly identical results. Experi-
mental procedures for this study were approved by Georgetown
University3s Institutional Review Board and written informed consent
was obtained from all subjects prior to the experiment.
2.3. Face discrimination experiment
Using face stimuli generated by a photorealistic face morphing sys-
tem (Blanz and Vetter, 1999) along twenty-ﬁve within-gender morph
lines based on ﬁfty individual prototype faces (200 by 256 pixels,
twenty-six females, see Fig. 1A), we tested subjects3 face discrimination
abilities using a two-alternative forced choice (2AFC) paradigm
(Fig. 1B). For each trial, after a 500 ms ﬁxation, the target face was pre-
sented for 200 ms, followed by a mask image for 400 ms, followed by
two choice faces presented side-by-side for 4000 ms or when partici-
pants responded (whichever came ﬁrst), and participants were asked
to judge which one of the two faces was the same as the target face.
The next trial would automatically start 1000 ms after subjects made a
response. If subjects failed to respond within 4000 ms, an auditory
alarm (“beep”) would be presented, and the next trial would start
1000 ms after the beep.
One of the choice faces was always the same as the sample face,
while the other choice face differed from theﬁrst one by one of four pos-
sible different levels of similarity. This was done by creating “morph
Table 1
Participant characteristics by HIV status.
Variables HIV+ women
(N = 15)
HIV− women
(N = 13)
p value
Age at visit (years), mean (sd) 50.1 (4.4) 50.2 (4.1) 0.953
Years of education, mean (sd) 13.5 (2.7) 15.5 (4.2) 0.147
MMSEa total score, mean (sd) 60.1 (7.4) 59.7 (6.7) 0.871
CESDb score at visit, mean (sd) 6.5 (9.2) 6.8 (10.2) 0.919
Race/ethnicity, n (%) 0.311
White, non-Hispanic 1 (6.7) 0 (0.0)
Black. non-Hispanic 13 (86.7) 10 (76.9)
Hispanic 1 (6.7) 3 (23.1)
Menopause, n (%) 9 (60.0) 5 (38.4) 0.256
Hepatitis C virus antibody positive,
n (%)
2 (13.3) 2 (15.4) 1.00
Recent marijuana use, n (%) 1 (6.7) 2 (15.4) 0.583
Recent crack use, n (%) 1 (6.7) 1 (7.7) 1.00
Current smoking, n (%) 4 (26.7) 4 (30.8) 1.00
Current drink, n (%) 0.0143
Abstainer 11 (73.3) 3 (23.1)
Light (b3 drinks/week) 2 (13.3) 8 (61.5)
Moderate (3–13 drinks/week) 2 (13.3) 2 (15.4)
Heavy (N=14 drinks/week) 0 (0.0) 0 (0.0)
CD4+ cell counts at visit, mean (sd) 702.5 (301.9)
Viral load at visit, median
(25%–75% IQRc)
20 (20.0, 186)
Antiretroviral medication use, n (%)
HAART 13 (86.7)
No therapy 2 (13.3)
Antiretroviral therapy adherence,
n (%)
100% 10 (76.9)
95%–99% 2 (15.4)
b75% 1 (7.7)
History of opportunistic infections,
n (%)
5 (33.3) 0 (0.0) 0.044
The bold fonts indicate the signiﬁcance as the numbers are p values.
a MMSE: Mini-mental state examination.
b CESD: Center for Epidemiologic Studies Depression Scale.
c IQR: Interquartile range.
Fig. 1. Face discrimination performance. (A) Shows an example “morph line” between a pai
photorealistic morphing system (42). The relative contribution of each face prototype change
amixture of 70% of the face on the far left and30% of the face on the far right. Four conditions,M3
in the present study. The difference between two prototype faces was deﬁned as 100%; 120% di
(B) Design of the 2AFC face discrimination experiment. Subjects viewed a target face, followed b
the test faces was identical to the previously presented target face. There were four levels of sha
performance from ﬁfteen HIV-positive women and thirteen controls. Error bars indicate SEM.
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images separated by a speciﬁed distance along this continuum (Fig. 1A).
We tested four different levels of intra-pair similarity, with shape differ-
ences of 30%, 60%, 90%, and 120% (conditions M3/6/9/12, respectively,
see Fig. 1A), with 100% corresponding to the distance between two pro-
totype faces, and 120% difference created by extrapolation (Blanz and
Vetter, 1999). Within each trial, the three faces were either all upright
or all inverted. Stimuli were presented to participants on an LCD moni-
tor on a dark background, 1024× 768 resolution, 60 Hz refresh rate, at a
distance of 60 cm. An in-house software package was used to present
the stimuli and to record the responses. Participants completed a total
of 800 trials (100 per condition) in sixteen blocks.
Face discrimination experiment was conducted outside of the MRI
scanner and after the participants ﬁnished the MRI scanning (with a
short break in between). The face discrimination data from three sub-
jects was discarded due to failure to follow instructions.
2.4. Functional localizer scans
To locate the FFA regions, a block designwas used to collectMRI im-
ages from two localizer scans for each subject (Haxby et al., 1999; Jiang
et al., 2013, 2006; Kanwisher et al., 1997). Brieﬂy, during each run, fol-
lowing an initial 10.2 s ﬁxation period, 50 grayscale images of faces,
houses, and scrambled faces were presented to participants in blocks
of 30.6 s (each image was displayed for 512 ms and followed by a
100 ms blank screen), and were separated by a 20.4 s ﬁxation block
(Fig. 2). Each block was repeated twice in each run, which lasted for
316.2 s, and participants were asked to passively view these images
while keeping their ﬁxation at the center of the screen. The face and
house images used in the localizer scans were downloaded from
Internet and post-processed using programs written in MATLAB (The
Mathworks, MA) to eliminate background variations, and to adjust
image size, luminance, and contrast. The ﬁnal size of all images wasr of face prototypes (shown at the far left and second from the right), created using the
s smoothly along the line. For example, the fourth face from the left (the third morph) is
/6/9/12,which correspond to shapedifferences of 30%, 60%, 90%, and 120%,were examined
fference was achieved by extrapolation along the morph line beyond face prototypes (42).
y a mask, followed by two test faces, presented side-by-side, and had to indicate which of
pe difference, M3/6/9/12, between the two test faces as explained in (A). (C) The averaged
Fig. 2. Functional localizer scans. Participants were asked to passively view blocks of face, house, and scrambled face images that were separated by ﬁxation blocks. The numbers (in black
font) indicate the ﬁrst and last MRI acquisition of each block. MRI images that were chosen for the local regional heterogeneity analysis are shown in red (face blocks) and blue (ﬁxation
blocks). Due to the lag of hemodynamic responses, for face blocks, the images from n0+ 2 to nm+ 2were used (n0 is the time point when face blocks started, and nm is the time point
when face blocks ended), and the images from n0+ 4 to nmwere used for ﬁxation blocks to avoid signal overlap from the blocks before and after it (n0 is the time point when a ﬁxation
block started, and nm is the time point when it ended).
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grid of 20 by 20 pixel elements while the outlines of the faces were kept
intact. The data from the localizer scans were also used in the local re-
gional heterogeneity analysis (see below) to probe the sparsity of FFA
neuronal activations.
2.5. Rapid event-related (ER) scans
MRI images from three (n = 22, ten HIV-negative) or four (n= 6,
three HIV-negative) ER scans were collected for each participant. Each
run lasted 538.56 s and had two 10.2 s ﬁxation periods, one at the begin-
ning and the other at the end. Between the two ﬁxation periods, a total
of 127 trials were presented to participants at a rate of one every 4.08 s.
During each trial (except null trials), two faces were displayed sequen-
tially (300mseachwith a 400msblank screen in-between), and follow-
ed by a 3080 ms blank screen (Jiang et al., 2013). For each run, the data
from the ﬁrst two trials were discarded, and analyses were performed
on the data of the other 125 trials — 25 each of the ﬁve different condi-
tions: three conditions of interest of varying intra-pair stimulus similar-
ity (M3/M6/M9, see Fig. 1A above) (Jiang et al., 2013), task trials, in
which an ‘oddball’ target face, which participants needed to identify,
could appear as either the ﬁrst or the second one of the pair of faces,
and null trials (Jiang et al., 2013). Performance inside the scanner was
nearly perfect and did not differ between the two groups of participants.
Trial order was randomized and counterbalanced using M-sequences
(Buracas and Boynton, 2002). While inside the scanner, participants
were asked to watch all the faces but only respond to instances of the
target face by pressing a button with the right hand. Morphed faces
(200 by 200 pixels) along ten within-gender morph lines of twenty in-
dividual prototype faces (ten females) were used, along with one addi-
tional oddball target face, different from the face prototypes used to
generate the morphed stimuli. The stimuli of both localizer and ER
scans were presented on black background using E-Prime software
(http://www.pstnet.com/products/e-prime/), back-projected on a
translucent screen located at the rear of the scanner, and viewed by par-
ticipants through amirrormounted on the head coil. The fMRI data from
the ER scans of one participants were discarded due to technical
problems.
2.6. MRI data acquisition
MRI data were acquired at the Georgetown University3s Center for
Functional and Molecular Imaging using an echo-planar imaging (EPI)
sequence on a 3.0 Tesla Siemens Trio scanner (Flip angle = 90°, TR =
2.04 s, TE = 29 ms, FOV = 205, 64 × 64 matrix) with a twelve-
channel head coil. Thirty-ﬁve interleaved axial slices (thickness =
4.0 mm, no gap; in-plane resolution = 3.2 × 3.2 mm2) were acquired
for the two functional localizer and all functional runs. At the end,
three-dimensional T1-weighted MPRAGE images (resolution
1 × 1 × 1 mm3) were sagittally-acquired from each subject (TR =1.9 s, TE=2.52ms, FOV=250, 1mmthicknesswith 18% oversampling,
creating 1 mm cubic voxels).
3. Data analysis
3.1. MRI data preprocessing
After discarding the images acquired during the ﬁrst three acquisi-
tions of each run, the EPI images were temporally corrected to themid-
dle slice, spatially realigned and unwrapped together with the images
from the localizer scans using the SPM8 software package (http://
www.ﬁl.ion.ucl.ac.uk/spm/software/spm8/), then all images were re-
sliced to 2 × 2 × 2 mm3, normalized to a standard MNI reference brain
in Talairach space, and smoothed with 6 mm Gaussian kernel using
SPM8.
The FFA regions were identiﬁed for each individual participant inde-
pendently with the data from the localizer scans. We ﬁrst modeled the
hemodynamic activity for each condition (face, scrambled face, and
house) in the localizer scans with the standard canonical hemodynamic
response function, then identiﬁed the FFA ROI with the contrast of
face versus house masked by the contrast of face versus baseline
(p b 0.0001). To obtain comparably-sized FFAs across participants, we
deﬁned the FFA as the ROI consisting of the 45 contiguous voxels with
the highest statistical threshold for each subject (Jiang et al., 2013).
After removing low frequency temporal noise from the EPI runs with
a high pass ﬁlter (1/128Hz), fMRI responsesweremodeledwith a design
matrix comprising the onset of eachnon-null trial andmovement param-
eters as regressors using SPM8.We extracted the hemodynamic response
for each subject in the right FFA, using a standard canonical hemodynam-
ic response function plus temporal derivative, with the MarsBar toolbox
(http://marsbar.sourceforge.net) and in-house software written in
Matlab (http://www.mathworks.com/products/matlab/).
3.2. Local regional heterogeneity analysis
Recentlywe introduced a novel technique to probe the sparseness of
neuronal activation patterns and provide an indication of neuronal se-
lectivity. The technique, called local regional heterogeneity analysis, or
Hcorr, is calculated as the standard error of voxel-wise correlations of
fMRI activation patterns in a pre-deﬁned functional or anatomical de-
ﬁned brain region (Jiang et al., 2013). This novel technique is motivated
by ﬁndings from monkey training studies showing that learning pro-
duces sparser codes, with neurons after training responding to fewer
stimuli, along with improved discrimination performance (Freedman
et al., 2006, 2006; Kobatake et al., 1998). In other words, the sparseness
of activation patterns is related to the speciﬁcity of neuronal tuning: the
high speciﬁc neurons produces a sparse neural code, as each neuron
only responds to a small set of stimuli highly similar to its preferred
stimulus/stimuli. In contrast, less speciﬁc neurons respond to a greater
number of dissimilar stimuli, leading to greater overlap in responses
among neurons and less sparse representations. This then predicts
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erogeneity in neural correlations (as small groups of neurons (e.g., FFA
neurons) preferring similar stimuli (e.g., faces) should show high corre-
lation with each other but low correlation with other neurons) com-
pared to the population with more broadly tuned neurons (in which
more neurons respond in a similar way, increasing the uniformity of
correlations). This hypothesis is supported by single-unit studies that
have found that neurons with similar tuning tend to show more corre-
lated ﬁring than neurons with dissimilar tuning (Bair et al., 2001;
Jermakowicz et al., 2009; Lin et al., 2014). Thus, when measured with
fMRI, neural tuning speciﬁcity should correlate with the degree of
sparseness, which in turn should correlate with the heterogeneity of
correlations, i.e., the standard deviation or standard error of correlations
between voxels. In other words, across subjects, a lower local regional
heterogeneity of correlations should be associated with a lower neural
speciﬁcity, and vice versa.
For the local regional heterogeneity analysis at FFA, we ﬁrst extract-
ed the raw time series data in the FFA from the ﬁrst localizer scan (see
Fig. 2) for each participant (with normalization but without additional
smoothing), followed by removal of the mean, any linear trends, and
low frequency variations. General linear model was used to regress
out variance due to head movements and global signal change
(Friston et al., 1995), then the fMRI data from every time point in the
face blocks and ﬁxation blocks (after compensating for delays caused
by the slow hemodynamic response) were used in a pair-wise correla-
tion analysis between each voxel, which resulted in a set of pairwise
correlation coefﬁcients (for n voxels), rij.
ri j ¼ corrðVoxi; VoxjÞ; i; j ∈1… n: ð1Þ
We then calculated a measure of local heterogeneity, Hcorr, as the
standard error of the mean (SEM) of those correlation coefﬁcients (rij,
i b j, because rij = rji, and rii = 1).
Hcorr ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
∑
n−1
i¼1
∑
n
j¼iþ1
ðri j−uÞ2
N  ðN−1Þ
vuuut
; where N ¼ ∑
n−1
i¼1
i; u ¼ 1
N
∑
n−1
i¼1
∑
n
j¼iþ1
rij:
ð2Þ
4. Results
4.1. Demographic, neuropsychological, medical, and other proﬁles of HIV-
positive patients and HIV-negative controls
As shown in Table 1, the HIV-positive group and HIV-negative group
werematched in terms of age, years of education, race/ethnicity, meno-
pause status, hepatitis C virus status, recent use of marijuana, crack, and
tobacco, alcohol use disorders, general neurocognitive function as mea-
sured by mini-mental status examination (MMSE), and depression
symptom as measured by Center for Epidemiological Studies Depres-
sion (CESD). The study participants had an average age of 50 years
and an average 14 years of education, with the vast majority of
women being Black, non-Hispanic. Among these HIV+women, the av-
erage CD4+ T cell count was 702 cells/mm3 and the median HIV RNA
level was 20 copies/mm3. About 87% of the HIV+womenwere on anti-
retroviral therapy, with about 93% of those on therapy having a ≥ 95%
self-reported adherence levels.
4.2. Comparable face discrimination performance between middle-aged
HIV+ women and age-matched HIV− controls
A mixed-design ANOVA on response accuracy, with two within-
subjects factors, face shape differences (M3/6/9/12) and face orienta-
tions (upright vs. inverted), and one between-subject factor, HIV status
(HIV-positive vs. HIV-negative), revealed a signiﬁcant difference be-
tween upright and inverted face conditions (F(1,25) = 80.258,p b 0.001) and between the four morph steps of face dissimilarities
(F(3,75) = 245.139, p b 0.001), and a signiﬁcant interaction between
face orientation and morph steps (F(3,75) = 15.516, p b 0.001), sug-
gesting participants were more accurate in discriminating upright
faces than inverted faces, with an increase in accuracy with increased
shape difference in face pairs and even more so with upright faces.
However, there were no signiﬁcant difference between the two groups
(p N 0.64), nor any signiﬁcant interactions betweenHIV status and other
within-subject factors (at least p N 0.14), suggesting that the HIV-
positive and HIV-negative subjects had comparable behavioral perfor-
mance in discriminating the morphed faces.
Furthermore, a samemixed-design ANOVA on reaction time also re-
vealed a signiﬁcant difference between upright and inverted face condi-
tions (F(1,25)= 4.423, p b 0.047) and between the four morph steps of
face dissimilarities (F(3,75)=34.182, p b 0.001), and a signiﬁcant inter-
action between face orientation and morph steps (F(3,75) = 21.945,
p b 0.001), suggesting participants were faster in discriminating upright
faces than inverted faces, with a decrease in reaction time with in-
creased shape difference in face pairs and even more so with upright
face. However, there were no signiﬁcant difference between the two
groups (p N 0.58), nor any signiﬁcant interactions between HIV status
and otherwithin-subject factors (at least p N 0.40). These results provid-
ed further support that the behavioral performance between the two
groups is comparable.
4.3. No signiﬁcant differences in fMRI response amplitude to faces in the FFA
measured via conventional fMRI techniques
To investigate whether potential early change in neuronal function
can be detected with conventional fMRI techniques that rely on com-
paring blood oxygen level dependent (BOLD) signal, all subjects partic-
ipated in an fMRI experiment that included two functional localizer runs
in which subjects viewed blocks of faces, scrambled faces, and houses,
separated by blocks of ﬁxation (Fig. 2). After identifying the right FFA
using the contrast of faces versus houses masked by faces versus base-
line in each individual subject (Jiang et al., 2013, 2006),we then extract-
ed the fMRI responses to faces in the right FFA from localizer scans.
There was no difference in fMRI responses to face between the HIV-
positive participants and HIV-negative controls (p N 0.43) (Fig. 3A).
4.4. FMRI-RA revealed a signiﬁcant decrease in neural speciﬁcity in the FFA
of HIV-positive individuals, in the absence of behavioral deﬁcits
Next, we applied fMRI-RA to examine the selectivity of face repre-
sentations in both HIV-positive participants and HIV-negative controls,
as a measure of neural speciﬁcity— that is, an earlier recovery from ad-
aptation suggests a sharper tuning to themorphed face, which in turn is
correlated with higher neural speciﬁcity, and vice versa.
The fMRI responses to pairs of faces in the M3/6/9 conditions were
extracted from the independently deﬁned right FFA ROI of each individ-
ual (same ROI as above). Amixed-design ANOVA, with a within-subject
factor (shape similarity between pairs of faces,M3/6/9), and a between-
subject factor (HIV status, HIV-positive vs. HIV-negative), revealed a sig-
niﬁcant interaction between the two factors (F(2,50) = 5.051, p b 0.05,
Bonferroni corrected for multiple comparisons of three main fMRI data
analyses as shown in Fig. 3), but no signiﬁcant effects of face shapes
(F(2,50) = 1.550, p= 0.226), nor of HIV status (F(1,25) = 1.310, p=
0.263). Post-hoc analyses revealed a trend of release from adaptation
from M3 to M6/9 conditions in HIV-negative controls (p b 0.037, one-
tailed t-test), but not in HIV-positive individuals (p N 0.621, one-tailed
t-test). These results suggest a broadened neuronal tuning to morphed
face in the FFA of HIV-positive middle-aged women, which in turn sug-
gests a signiﬁcant decrease in neural speciﬁcity, despite a comparable
face discrimination performance between the HIV-positive and HIV-
negative participants (Fig. 3B).
Fig. 3. FMRI data. (A) Conventional fMRI techniques revealed no difference between the middle-aged HIV-positive women and age-matched controls, with compatible mean fMRI re-
sponses to face, house, and scrambled face from the two functional localizer scans. In contrast, both fMRI-RA (B) orHcorr (C) revealed a reduced neural speciﬁcity in the FFA of HIV-positive
women than that of HIV-negative controls. (B) Three conditions of interests, M3/6/9, were included in the fMRI-RA experiment. In contrast to a full recovery from adaptation at M6 con-
dition in controls (similar to what we have found in healthy younger adults (Jiang et al., 2006)), there was no recover from adaptation (even atM9 condition) in HIV-positive individuals,
suggesting a signiﬁcant decrease in neural speciﬁcity (reﬂecting as a broadened neuronal tuning) in the FFA of HIV+women. (C) Local voxel-wise correlations also revealed a lowerHcorr
value in the FFA of HIV-positive individuals than HIV-negative controls, conﬁrming a reduced neural speciﬁcity in FFA, even in the absence of behavioral deﬁcits. Error bars showwithin-
subject SEM.
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reduction in neural speciﬁcity in the FFA of HIV-positive patients
The data from the fMRI-RA experiment revealed a signiﬁcant decrease
in neural speciﬁcity in the FFA of middle-aged HIV-positive participants,
in the absence of behavioral impairments. Here we sought to indepen-
dently conﬁrm this ﬁnding using the novel fMRI data analysis technique,
local regional heterogeneity analysis, or Hcorr, which we recently devel-
oped to estimate neural speciﬁcity. Indeed, this novel analysis revealed
a trendof difference inHcorrbetween the twogroups (pb 0.126, two tailed
t-test, Bonferroni corrected for multiple comparisons of three main fMRI
data analyses as shown in Fig. 3). However, removing one outlier HIV+
subject whose Hcorr is more than 4 standard deviation from the mean of
HIV+ group revealed a highly signiﬁcant difference between the two
groups (p b 0.05, corrected), conﬁrming an early decrease in neural spec-
iﬁcity amongmiddle-aged HIV-positive women, despite being on HAART
with well-controlled disease (see Table 1). While the two independent
techniques with independent fMRI data sets revealed converging results,
the differences between the two groups are relatively small, i.e., the group
difference in Hcorr was non-signiﬁcant with a Bonferroni correction for
multiple comparisons. Such a relatively weak difference suggests that
neuronal dysfunction in these HIV-positive individuals are subtle and
might be at early stage of disease, in line with their “normal” behavioral
performance in discriminating face shapes (Fig. 1). Therefore, future stud-
ies are needed to validate and advance this novel Hcorr technique and its
application in studying HAND with behaviorally impaired HIV-positive
patients, with whom a larger difference in Hcorr and fMRI-adaptation is
expected.5. Discussion
There is a high prevalence of mild forms of HAND in the cART era
(Heaton et al., 2010), that has been associated with increased risk of vi-
rologic failure, symptomatic cognitive impairments, andmortality (Ellis
and Deutsch, 1997; Grant et al., 2014). Therefore there is pressing need
to ﬁnd biomarkers that can identify neural targets for early andmore ef-
fective treatments (especially in those without a behavioral deﬁcit yet),
in order to prevent progression to symptomatic HAND and to preserve
and improve neurocognitive functions. Using two different fMRI tech-
niques, fMRI-RA andHcorr, we provided converging evidence that neural
speciﬁcity (or the speciﬁcity of neuronal tuning) is able to detect neuro-
nal dysfunction in HIV-positive women, prior to the onset of behavioral
deﬁcits. These results suggest that neural speciﬁcity could have a poten-
tial to serve as a non-invasive biomarker of HAND disease progression,
especially when behavioral assays cannot detect the changes.
Previous fMRI studies have found that neural speciﬁcity is sensitive
to training/learning (with an increase in neural speciﬁcity along with
an increase in behavioral performance) (Jiang et al., 2007), disease
(with a decrease in neural speciﬁcity along with a decrease inbehavioral performance) (Jiang et al., 2013), and aging (Goh et al.,
2010; Lee et al., 2011). In particular, neural speciﬁcity has been shown
to be a sensitive measure of cognitive aging being lower in older com-
pared to younger adults (Goh et al., 2010; Lee et al., 2011). It has been
proposed that the reduction in neural speciﬁcity in the aged brain
might reﬂect an age-related neural dedifferentiation (Li et al., 2001),
that is, neurons in the aged brain become less selective thus less able
to support the processing of stimuliwith subtle differences,which even-
tually lead to a decrease in cognitive performance. Data from single-unit
recording studies of animals (Leventhal et al., 2003) and neuroimaging
studies of human subjects (Goh et al., 2010; Lee et al., 2011) have pro-
vided direct experimental support to the age-related neural dedifferen-
tiation theory. In particular, using a paradigm similar to the present
study, a recent cognitive aging study (Goh et al., 2010) has found that,
despite comparable behavioral performance in discriminating faces
with parametric shape changes between young and older adults, the
neural speciﬁcity in the FFA of older adults was reduced. These earlier
ﬁndings suggest that, in healthy older adults, a reduction in neural spec-
iﬁcity might precede the onset of detectable behavioral impairments.
Interestingly, we also found a reduced neural speciﬁcity in the FFA of
HIV+ women in the absence of behavioral deﬁcits, suggesting that the
early pathological changes among these middle-aged HIV+ individuals
might resemble those often observed in the elderly adults, consistent
with the HIV-induced accelerated/premature aging hypothesis (Deeks,
2011; Ernst and Chang, 2004; Guaraldi et al., 2011; High et al., 2012;
Martin and Volberding, 2010; Meir-Shafrir and Pollack, 2012; Önen
and Overton, 2011; Smith et al., 2012). These early neuronal dysfunc-
tions — reduced neural speciﬁcity, when combined with additional
aging-related neural dedifferentiation, might be responsible for the
lower cognitive reserve (van Gorp et al., 1994) and higher risk of cogni-
tive impairments (Deeks, 2011; Martin and Volberding, 2010; Meir-
Shafrir and Pollack, 2012) among older HIV+ adults.
While fMRI-RA is currently the standard fMRI technique to estimate
neural speciﬁcity, it requires a lengthy scanning time (as about
30–40 min in the present study), which signiﬁcantly limits the feasibil-
ity of using it in a typical clinical setting. In contrast, we recently devel-
oped a novel fMRI data analysis technique, local regional heterogeneity
analysis, or Hcorr, to estimate neural speciﬁcity (Jiang et al., 2013). This
novel technique is motivated by ﬁndings from monkey training studies
showing that learning produces sparser codes, with neurons after train-
ing responding to fewer stimuli, along with improved discrimination
performance (Freedman et al., 2006, 2006; Kobatake et al., 1998). We
have shown that this novel Hcorr technique is able to estimate neural
speciﬁcity with fMRI data from a merely 5-minute scan, as in the pres-
ent and our previous studies (Jiang et al., 2013), making it a more feasi-
ble and convenient clinical diagnostic tool to estimate neural speciﬁcity
than fMRI-RA in routine clinical practice. Another unique advantage
thatHcorr has over fMRI-RA is thatHcorr has the potential to probe neural
speciﬁcity at any functionally or anatomically deﬁned brain region using
a single data set, including resting state scans.More speciﬁcally, because
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et al., 2009; Lin et al., 2014) found that pair-wise correlations between
two neurons in the presence of visual stimuli can be detected in the
absence of stimuli, thus the voxel-wise correlations and Hcorr within a
given region should be similar with or without a task. Similar neural
mechanismsmight also underlie the ﬁndings from fMRI studies of rest-
ing state (Fox and Raichle, 2007; Smith et al., 2009). This unique feature
makesHcorr an ideal tool to examinewidespreadpathological changes in
diseases like HAND (Clifford and Ances, 2013; Lindl et al., 2010). How-
ever, future studies are needed to verify and validate this novel Hcorr
technique in studying HAND as the difference in Hcorr in the present
studydid not survive correction formultiple comparisons. The relatively
weak effect might be due to the following factors: i) FFA might not be
the mostly affected brain regions due to HIV-infection, therefore it
would be interesting to examine neural speciﬁcity in other more clini-
cally relevant brain regions in future studies, such as hippocampus
(our preliminary results indeed reveal a decrease in neural speciﬁcity
in the hippocampus of HIV-positive women); ii) the neuronal dysfunc-
tion at FFA is still subtle in these HIV-positive women, as indicated by
their “normal” behavioral performance in face discrimination, therefore
future studies are needed to examine changes in neural speciﬁcity in
HIV-positive individuals with behavioral symptoms, with whom we
predict a more signiﬁcant decrease in neural speciﬁcity; and iii) the
HIV-positive population is rather heterogeneous, i.e., removing one out-
lier HIV+ subject whose Hcorr is more than 4 standard deviation from
the mean of HIV+ group dramatically improved the signiﬁcance in
group comparison, therefore a future study with a larger sample size
should be conducted to validate and advance the novel Hcorr technique
and its application in HAND. Nevertheless, our results thus suggest
that Hcorr can be an excellent choice of clinical tool to estimate the de-
crease in neural speciﬁcity in individuals with HIV-infection, especially
in those with no or mild clinical symptoms of HAND.
However, one key question remains to be addressed by future stud-
ies: what is/are the driving force(s) of the decrease in neural speciﬁcity
among HIV+ adults? Computational simulation and theoretical works
of cognitive aging have proposed that increased neuronal noise due to
reduced dopamine activity (Li et al., 2001) and decreased neuronal se-
lectivity due to age-related synaptic injury (Morrison and Baxter,
2012) might be responsible for age-related reduction in neural speciﬁc-
ity. Coincidently, HIV infection is known to impair dopamine transport-
er functions (Purohit et al., 2011) and synaptic functions (Atluri et al.,
2013; Ellis et al., 2007; Ellis, 2010; Everall et al., 1999; Masliah et al.,
1992; Nath and Steiner, 2014). For instance, dopamine reduction has
been found in the HIV-infected brain (Wang et al., 2004) and is related
to the concentration of HIV-1 RNA (Kumar et al., 2009) and cognitive
impairments (Nath et al., 2000). The synaptodendritic injury and its
manifestation have been proposed as the key contributor to the
neurocognitive impairments among HIV-infected adults in the cART
era (Ellis et al., 2007). Based on data from the present and earlier stud-
ies, we propose that, similar to HIV-negative older adults, the reduced
neural speciﬁcity among HIV+ individuals might be due to increased
neuronal noise resulting from impaired dopamine system and
decreased neuronal selectivity due to synaptodendritic injury; and the
reduction in neural speciﬁcity might serve as a biomarker to identify
brain regions that are most vulnerable to HIV infection (i.e., regions
with highest reduction in neural speciﬁcity) and individuals at risk of
symptomatic neurocognitive impairments. However, we acknowledge
that there is no experimental proof support of our novel hypothesis. In
addition, the relationship between dopamine activity, synaptodendritic
injury, neural speciﬁcity, and neurocognitive functions is not clear nor
straightforward. For instance, in contrast to the unidirectional decease
of dopamine activity due to aging, HIV infection could also lead to an el-
evated levels of dopamine in the dopaminergic synapses in the early
asymptomatic stage of HIV infection (Scheller et al., 2010). Therefore,
it remains to be tested whether there is a change in neural speciﬁcity
right after seroconversion, as previous studies have suggested thepresence of neuronal dysfunction in the acute and early period of infec-
tion (Doyle et al., 2013), thus future interdisciplinary studies are needed
to relate fMRI (especially Hcorr) measured neural speciﬁcity to neuronal
dysfunction such as dopamine activity, synaptodendritic injury, and
ultimately to neurocognitive functions, in order to build a strong foun-
dation for the clinical applications of this novel and non-invasive bio-
marker using the Hcorr technique. Furthermore, future studies are also
needed to conﬁrm whether reduced neural speciﬁcity, as well as the
novel Hcorr technique, can be used to examine early neuronal dysfunc-
tion in other HIV+ patients, including middle-aged and older men
with HIV-infection, and in other brain regions such as hippocampus.
In addition, we predict that the reduction in neural speciﬁcity might
be more signiﬁcant in HIV+ individuals with detectable behavioral im-
pairments. However, such a prediction needs to be veriﬁedwith at least
three groups of participants, HIV+ individuals with or without measur-
able behavioral impairments, and negative controls.
In summary, our study revealed a lower neural speciﬁcity in cognitive-
ly normal HIV+women compared to matched HIV−women, in the ab-
sence of behavioral deﬁcits, and this change in neural speciﬁcity can be
detected via both Hcorr and fMRI-RA techniques. Furthermore, the novel
Hcorr technique could be used as a clinical tool to assess the risk/severity
of HAND, due to its simplicity, robustness, and high sensitivity.Conﬂict of interest
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